Literature DB >> 20463109

APOE epsilon4 and cognitive dysfunction in multiple sclerosis: a review.

Omar Ghaffar1, Anthony Feinstein.   

Abstract

The authors present a literature review exploring the possible association between APOE epsilon4 and cognitive dysfunction in multiple sclerosis. Differences in magnetic resonance (MR)-elicited brain pathology between epsilon4+ and epsilon4- multiple sclerosis patients were also considered. Overall, the cognitive literature suggests the likelihood of a gene-cognition relationship. A less certain picture pertains to the gene-MR data. Methodological considerations, however, leave many questions unanswered and the conclusions should be viewed in this light. No study has yet combined neuropsychological inquiry, brain imaging, and genetic determination, an approach that has the potential to pull together various pieces of the puzzle.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20463109     DOI: 10.1176/jnp.2010.22.2.155

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  4 in total

Review 1.  Pharmacogenomics and multiple sclerosis: moving toward individualized medicine.

Authors:  Manuel Comabella; Koen Vandenbroeck
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

Review 2.  A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward.

Authors:  Michaël E Belloy; Valerio Napolioni; Michael D Greicius
Journal:  Neuron       Date:  2019-03-06       Impact factor: 17.173

Review 3.  Risk factors for and management of cognitive dysfunction in multiple sclerosis.

Authors:  Ralph H B Benedict; Robert Zivadinov
Journal:  Nat Rev Neurol       Date:  2011-05-10       Impact factor: 42.937

4.  ApoE4-positive multiple sclerosis patients are more likely to have cognitive impairment: a cross-sectional study.

Authors:  Farshid Mashayekhi; Saeed Sadigh-Eteghad; Amirreza Naseri; Milad Asadi; Negin Abbasi Garravnd; Mahnaz Talebi
Journal:  Neurol Sci       Date:  2021-06-12       Impact factor: 3.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.